Bush Tia L 4
4 · Centessa Pharmaceuticals plc · Filed Sep 11, 2025
Insider Transaction Report
Form 4
Bush Tia L
Chief Technology & Quality Ofc
Transactions
- Exercise/Conversion
Ordinary Shares
2025-09-09$8.01/sh+24,792$198,584→ 146,295 total - Exercise/Conversion
Ordinary Shares
2025-09-10$9.42/sh+25,000$235,500→ 146,503 total - Sale
Ordinary Shares
2025-09-10$22.00/sh−25,000$550,000→ 121,503 total - Exercise/Conversion
Share Option (right to buy)
2025-09-10−25,000→ 475,338 totalExercise: $9.42Exp: 2031-05-07→ Ordinary Shares (25,000 underlying) - Sale
Ordinary Shares
2025-09-09$20.00/sh−24,792$495,840→ 121,503 total - Exercise/Conversion
Share Option (right to buy)
2025-09-09−24,792→ 145,208 totalExercise: $8.01Exp: 2034-02-01→ Ordinary Shares (24,792 underlying)
Footnotes (4)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2024.
- [F3]1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2024.
- [F4]25% of the shares subject to such option shall vest and become exercisable on May 20, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.